Abstract

Sickle cell anemia is a manifestation of a single point mutation in hemoglobin, but inflammation and pain are the insignia of this disease which can start in infancy and continue throughout life. Earlier studies showed that mast cell activation contributes to neurogenic inflammation and pain in sickle mice. Morphine is the common analgesic treatment but also remains a major challenge due to its side effects and ability to activate mast cells. We, therefore, examined cannabinoid receptor-specific mechanisms to mitigate mast cell activation, neurogenic inflammation and hyperalgesia, using HbSS-BERK sickle and cannabinoid receptor-2-deleted sickle mice. We show that cannabinoids mitigate mast cell activation, inflammation and neurogenic inflammation in sickle mice via both cannabinoid receptors 1 and 2. Thus, cannabinoids influence systemic and neural mechanisms, ameliorating the disease pathobiology and hyperalgesia in sickle mice. This study provides 'proof of principle' for the potential of cannabinoid/cannabinoid receptor-based therapeutics to treat several manifestations of sickle cell anemia.

MeSH

Hematology, Anemia, Sickle Cell, Cannabinoids, Hyperalgesia, Pain, Therapeutics, Mast Cells, Neurogenic Inflammation, Receptors, Cannabinoid

Cited by

• Characterization of functional brain activity and connectivity using EEG and fMRI in patients with sickle cell disease. Neuroimage Clin, 2017
• Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol, 2018
• Tetrahydrocannabinol Reduces Hapten-Driven Mast Cell Accumulation and Persistent Tactile Sensitivity in Mouse Model of Allergen-Provoked Localized Vulvodynia. Int J Mol Sci, 2019
• Mast cell-neural interactions contribute to pain and itch. Immunol Rev, 2019
• Quantification of pain in sickle mice using facial expressions and body measurements. Blood Cells Mol Dis, 2016
• Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series. Naunyn Schmiedebergs Arch Pharmacol, 2022
• Precision, integrative medicine for pain management in sickle cell disease. Front Pain Res (Lausanne), 2023
• Electroacupuncture in conscious free-moving mice reduces pain by ameliorating peripheral and central nociceptive mechanisms. Sci Rep, 2016
• Mechanisms of pain in sickle cell disease. Br J Pain, 2021
• Genetic inactivation of calpain-1 attenuates pain sensitivity in a humanized mouse model of sickle cell disease. Haematologica, 2018
• Targeting novel mechanisms of pain in sickle cell disease. Blood, 2017
• Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation. Proc Biol Sci, 2022
• Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. J Clin Med, 2022
• Exploring Localized Provoked Vulvodynia: Insights from Animal Model Research. Int J Mol Sci, 2024
• Comparative Analysis of Pain Behaviours in Humanized Mouse Models of Sickle Cell Anemia. PLoS One, 2017
• Targeting novel mechanisms of pain in sickle cell disease. Hematology Am Soc Hematol Educ Program, 2018
• Targeting pain at its source in sickle cell disease. Am J Physiol Regul Integr Comp Physiol, 2019
• Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA Netw Open, 2020
• Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease. J Clin Med, 2020
• Mast Cell Neural Interactions in Health and Disease. Front Cell Neurosci, 2019